Abstract
Tumoral angiogenesis has been described as associated with poor prognosis in breast cancer, particularly for node negative breast cancer. The purpose of this study was to evaluate the influence of angiogenesis in node‐positive breast cancer and particularly its potential impact on adjuvant chemotherapy.
Patients and methods: One hundred and thirty‐five node‐positive breast cancer patients who received anthracycline or derivative based adjuvant chemotherapy were selected from the data base of the Institut Paoli Calmettes. Angiogenesis was evaluated using CD31 antibody. Other prognosis variables studied were: hormonal status, tumor size, hormonal receptors, Elston and Ellis grade, and number of involved lymph nodes.
Results: In multivariate analysis, a high level of angiogenesis was independently associated with a diminution of survival (p=0.007), and of metastasis‐free survival (p=0.003). Other variables associated with poor survival were progesterone receptor status p=0.003) and Elston' grade p=0.003), and with metastasis‐free survival, progesterone receptor status (p=0.018).
Conclusion: Tumoral angiogenesis appears to be an independent prognostic factor for node‐positive breast cancer, when treated with adjuvant chemotherapy. Adjuvant strategies for patients with a high level of angiogenesis should be discussed.
Similar content being viewed by others
References
Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339(8784): 1–15, 1992
Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339(8785): 71–85, 1992
Gasparini G, Pozza F, Harris AL: Evaluating the potential usefulness of new prognostic and predictive indicators in nodenegative breast cancer patients. J Natl Cancer Inst 85(15): 1206–1219, 1993
Perren TJ: c-erbB-2 oncogene as a prognostic marker in breast cancer. Br J Cancer 63: 328–332, 1991
Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, Henderson IC: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. New Engl J Med 330: 1260–1266, 1994
Kovach JS, Hartmann A, Blaszyk H, Cunningham J, Schaid D, Sommer SS: Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc Natl Acad Sci USA 93: 1093–1096, 1996
Elledge RM, Gray R, Mansour E, Yu Y, Clark GM, Ravdin P, Osborne CK, Gilchrist K, Davidson NE, Robert N, Tormey DC, Allred DC: Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J Natl Cancer Inst 87(16): 1254–1256, 1995
Silvestrini R, Benini E, Veneroni S, Daidone MG, Tomasic G, Squicciarini P, Salvadori B: p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol 14(5): 1604–1610, 1996
Gasparini G, Barbareschi M, Doglioni C, Dalla Palma P, Mauri FA, Boracchi P, Bevilacqua P, Caffo O, Morelli L, Verderio P, Pezzella F, Harris AL: Expression of bcl-2 protein predicts efficacy of adjuvant treatment in operable node-positive breast cancer. Clin Cancer Res 1: 189–198, 1995
Fidler IJ, Ellis LM: The implication of angiogenesis for the biology and therapy of cancer metastasis. Cell 79: 185–188, 1994
Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27–31, 1995
Gasparini G, Bonoldi E, Viale G, Verderio P, Boracchi P, Panizzoni GA, Radealli U, Di Bacco A, Guglielmi RB, Bevilacqua P: Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas. Int J Cancer 69: 205–211, 1996
Fontanini G, Vignati S, Lucchi M, Mussi A, Calcinai A, Boldrini L, Chiné S, Silvestri V, Angeletti CA, Basolo F, Bevilacqua G: Neoangiogenesis and p53 protein in lung cancer: Their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression. Br J Cancer 75(9): 1295–1301, 1997
Gasparini G, Harris AL: Clinical importance of the determination of tumor angiogenesis in breast carcinoma: Much more than a new prognostic tool. J Clin Oncol 13(3): 765–782, 1995
Folkman J: The influence of angiogenesis research onmanagement of patients with breast cancer. Breast Cancer Res Treat 36: 109–118, 1995
Barinaga M: Designing therapies that target tumor blood vessels. Science 275: 482–484, 1997
Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: Experience from a large study with long term follow-up. Histopathology 19: 403–410, 1991
Jacquemier JD, Charpin C, Martin PM: Etude immunohistochimique par anticorps monoclonal (H222SP gamma) des récepteurs oestrogéniques: Corrélation avec l' analyse biochimique par radioligand pour 115 carcinomas mammaires. Bull Cancer 73: 107–119, 1986
Jacquemier JD, Penault-Llorca FM, Bertucci F, Sun ZZ, Houvenaeghel GF, Geneix JA, Puig BD, Bardou VJH, Hassoun JA, Birnbaum D, Viens PJ: Angiogenesis as a prognostic marker in breast carcinoma with conventional adjuvant chemotherapy: A multiparametric and immunohistochemical analysis. J Pathol 184: 130–135, 1998
Vermeulen PB, Libura M, Libura J, O'Neill PJ, van Dam P, van Marck E, van Oosterom AT, Dirix LY: Influence of investigator experience and microscopic field size on microvessel density in node-negative breast carcinoma. Breast Cancer Res Treat 42: 165–172, 1997
Barbareschi M, Weidner N, Gasparini N, Morrelli L, Forti S, Eccher C, Fina P, Caffo O, Leonardi E, Mauri F, Bevilacqua P, Dalla Palma P: Microvessel density quantification in breast carcinomas. Appl Immunohistochem 3: 75–84, 1995
Kaplan EL, Meier P: Non parametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481, 1971
Peto R, Peto J: Asymptomatically efficient rank invariant test procedures. J R. Stat Soc A 135: 185–198, 1972
Cox DR: Regression models and life table (with discussion). J R Stat Soc B 34: 187–220, 1972
Peters WP, Ross M, Vredenburgh JJ, Meisenberg B, Marks LB, Winer E, Kurtzberg J, Bast RC Jr, Jones R, Shpall E, Wu K, Rosner G, Gilbert C, Mathias B, Coniglio D, Petros W, Henderson IC, Norton L, Weiss RB, Budman DR, Hurd D: High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 11(6): 1132–1143, 1993
Gianni AM, Siena S, Bregni M, Di Nicola M, Orefice S, Cusumano F, Salvadori B, Luini A, Greco M, Zucali R, Rilke F, Zambetti M, Valagussa P, Bonadonna G: Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: Five-year results. J Clin Oncol 15(6): 2312–2321, 1997
Weidner N, Semple JP, Welch WR, Folkman J: Tumor angiogenesis and metastasis – Correlation in invasive breast carcinoma. N Engl J Med 324(1): 1–8, 1991
Van Hoef MEHM, Knox WF, Dhesi SS, Howell A, Schor AM: Assessment of tumour vascularity as a prognostic factor in lymph node negative invasive breast cancer. Eur J Cancer 29A(8): 1141–1145, 1993
Gasparini G, Weidner N, Bevilacqua P, Maluta S, Dalla Palma P, Caffo O, Barbareschi M, Boracchi P, Marubini E, Pozza F: Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 12(3): 454–466, 1994
Heimann R, Ferguson D, Powers C, Recant WM, Weichselbaum RR, Hellman S: Angiogenesis as a predictor of longterm survival for patients with node-negative breast cancer. J Natl Cancer Inst 88(23): 1764–1769, 1996
Axelsson K, Ljung B-ME, Moore DH II, Thor AD, Chew KL, Edgerton SM, Smith HS, Mayall BH: Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J Natl Cancer Inst 87(13): 997–1008, 1995
Toi M, Kashitani J, Tominaga T: Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma. Int J Cancer 55: 371–374, 1993
Horak ER, Leek R, Klenk N, Lejeune S, Smith K, Stuart N, Greenall M, Stepniewska K, Harris AL: Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 340: 1120–1124, 1992
Weidner N, Folkman J, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G: Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84(24): 1875–1887, 1992
Gasparini G, Toi M, Gion M, Verderio P, Dittadi R, Hanaïani M, Matsubara I, Vinante O, Bonoldi E, Boracchi P, Gatti C, Suzuki H, Tominaga T: Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 89(2): 139–147, 1997
Toi M, Inada K, Hoshina S, Suzuki H, Kondo S, Tominaga T: Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer. Clin Cancer Res 1: 961–964, 1995
Protopapa E, Delides GS, Révész L: Vascular density and the response of breast carcinomas to mastectomy and adjuvant chemotherapy. Eur J Cancer 29A(10): 1391–1393, 1993
Paulsen T, Aas T, Borresen A-L, Verhaug JE, Lonning PE, Akslen LA: Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer. Int J Cancer 74: 138–140, 1997
Gasparini G, Fox SB, Verderio P, Bonoldi E, Bevilacqua P, Boracchii P, Dante S, Marubini E, Harris AL: Determination of angiogenesis adds information to estrogen receptor status in predicting the efficacy of adjuvant tamoxifen in nodepositive breast cancer patients. Clin Cancer Res 2: 1191–1198, 1996
Fox SB, Leek RD, Bliss J, Mansi JL, Gusterson B, Gatter KC, Harris AL: Association of tumor angiogenesis with bone marrow micrometastases in breast cancer patients. J Natl Cancer Inst 89(14): 1044–1049, 1997
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Viens, P., Jacquemier, J., Bardou, V. et al. Association of angiogenesis and poor prognosis in node‐positive patients receiving anthracycline‐based adjuvant chemotherapy. Breast Cancer Res Treat 54, 205–212 (1999). https://doi.org/10.1023/A:1006112927565
Issue Date:
DOI: https://doi.org/10.1023/A:1006112927565